Cellular Origins and Fresenius Kabi have completed the first phase of a CGT manufacturing collaboration announced in October 2024.

CAMBRIDGE, England & STEVENAGE, England--(BUSINESS WIRE)--Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and ...

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs ...

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an ...

Reducing manual touchpoints is an important part of supporting more consistent and scalable manufacturing processes.